Cardiovascular News
Cardiovascular effects of Japan's 2011 earthquake and tsunami: Incidence rises with the seismic peak
The Japanese earthquake and tsunami of 11 March 2011, which hit the north-east coast of Japan with a magnitude of 9.0 on the Richter scale, was one of the largest ocean-trench earthquakes ever recorded in Japan. The tsunami caused huge damage, including 15,861 dead and 3018 missing persons, and, as of 6 June 2012, 388,783 destroyed homes.
Following an investigation of the ambulance records made by doctors in the Miyagi prefecture, close to the epicentre of the earthquake and where the damage was greatest, cardiologist Hiroaki Shimokawa and colleagues from the Tohoku University Graduate School of Medicine at Sendai, Japan, found that the weekly occurrence of five conditions – heart failure, acute coronary syndrome (including unstable angina and acute myocardial infarction), stroke, cardio-pulmonary arrest and pneumonia – all increased sharply soon after the earthquake occurred.
Such reactions – in acute coronary syndrome, stroke and pulmonary embolism – have been reported before, said Shimokawa, in Japan, China and the USA. However, these studies reported only the short-term occurrence of individual cardiovascular disease events, and the mid-term cardiovascular disease effects of such great earthquakes remain to be elucidated. To this end, the study examined all ambulance transport records in the Miyagi prefecture from 11 February to 30 June for each year from 2008 to 2011 (ie, four weeks before to 16 weeks after 11 March, a total of 124,152 records). Incidence records from before, during and after the earthquake disaster were compared, the aftershocks counted and recorded according to a seismic intensity of 1 or greater.
The number of aftershocks in the Miyagi prefecture was frequent during the six weeks after the earthquake, and the second peak was noted as a large aftershock on 7 April 2011 (magnitude of 7.0). Compared with the previous three years, the significant increases in the occurrence of heart failure and pneumonia were steadily prolonged for more than six weeks after the tsunami struck. On the other hand, the incident increases in stroke and cardio-pulmonary arrest followed the pattern of the first and aftershock seismic peaks. The rapid increases in the occurrence of acute coronary syndromes and cardio-pulmonary arrest was followed by a sharp and significant decline. Interestingly, said Shimokawa, age, sex or residence area did not significantly affect the occurrences of cardiovascular disease during or following the tsunami.
"To the best of our knowledge," he added, "this is the first report to describe the mid-term course of major cardiovascular events and pneumonia after a great earthquake in a large population. In particular, our findings provide the first evidence that the incidence of heart failure was markedly increased over a long period afterwards." Prevalence of pneumonia, a well known risk factor for deteriorating heart failure, was significantly increased.
The Tohoku University study also found – as reflected in self-monitoring measurements – that blood pressure was significantly elevated after the earthquake. However, transport disruption following the tsunami interrupted delivery of regular medications, such as antihypertensive or antithrombotic drugs, and this may have contributed to the increased cardiovascular events. There was also an increase in the occurrences of ventricular tachyarrhythmias in patients with implantable cardiac defibrillators.
"Taken together," said Shimokawa, "we consider that discontinuation of drugs, activated sympathetic nervous system, rising blood pressure, and the increased occurrence of tachyarrhythmia and infections were all involved in the increased occurrence of cardiovascular events after the Great Earthquake of Japan."
Results from EXTRACT-PE trial of Penumbra's Indigo aspiration system published
"This is the tip of the iceberg" warns BHF as cardiothoracic surgeries cancelled
The Foundry announces first-in-human procedure in study of Half Moon TMVR device
InnovHeart announces first-in-human use of its Saturn mitral valve
What does SCOPE II tell us about TAVI device trials?
Sharing international insight to improve the cardiovascular treatment pathway
Optimising pharmacology after transcatheter aortic valve replacement: Lessons from the POPular TAVI trial
Michael Reardon
J Dawn Abbott
Vinod Thourani